Buprenorphine

BreastfeedingPediatric
  • TRADE NAMES: Probuphine (Braeburn); Suboxone (Reckitt Benckiser); Subutex (Reckitt Benckiser); Temgesic; Transtec (Napp)
  • INDICATIONS: Opioid dependence, moderate to severe pain
  • CLASS: Analgesic, Mixed opioid agonist/antagonist, Narcotic
  • HALF-LIFE: 37 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Antihistamines, Atazanavir, Azole antifungals, Benzodiazepines, Boceprevir, Carbamazepine, Cimetidine, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Delavirdine, Diazepam, Efavirenz, Erythromycin, HIV protease inhibitors, Hydrocodone, Hydromorphone, Ketoconazole, Ketorolac, Linezolid, Macrolide antibiotics, Morphine, Neuroleptics, Oxymorphone, Phenobarbital, Phenytoin, Rifampin, Ritonavir, Tapentadol, Tipranavir

PREGNANCY CATEGORY: C

Suboxone contains naloxone; Probuphine is an implant for subdermal administration.

ABUSE POTENTIAL, LIFE-THREATENING RESPIRATORY DEPRESSION, and ACCIDENTAL EXPOSURE

Probuphine: IMPLANT MIGRATION, PROTRUSION, EXPULSION, and NERVE DAMAGE ASSOCIATED WITH INSERTION and REMOVAL


See full prescribing information for complete boxed warning.

Our database has 82 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
GENITOURINARY
OTIC
OCULAR
LOCAL
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric